Influenza vaccines: antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population.
The humoral immune response generated by two commercial influenza vaccines was evaluated in a randomised, double-blind trial performed in the Public Department of Dolo Health District (North-east Italy) during the winter season 1997-1998. Ninety-eight subjects were immunised with a split virus vaccine and ninety-six with a MF59-adjuvanted subunit virus vaccine (SU/MF59). The pre- and postvaccination (approximately 30 days) antibody titres were determined by hemagglutination inhibition test (HI). After immunisation protective titre rates (> or = 1:40) were near 100% against virus A strain and 82.5% against B strain. Both vaccines caused significant rises in geometric mean antibody titres (GMTs); however, people who received SU/MF59 vaccine were found to develop a greater immune response compared to the group immunised with SVV. According to logistic regression analysis the unprotective prevaccination immune status and the use of SU/MF59 were identified as independent factors significantly increasing the response to immunisation.
Menegon
T
T
Institute of Hygiene, University of Padua, Italy.
Baldo
V
V
Bonello
C
C
Dalla Costa
D
D
Di Tommaso
A
A
Trivello
R
R
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000917:Antibody Formation; D004311:Double-Blind Method; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged
D007252:Influenza Vaccines